Alma Viso Beronda-rekin lankidetzan egindako argitalpenak (28)

2017

  1. Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling

    Chemistry - A European Journal, Vol. 23, Núm. 7, pp. 1676-1685

2011

  1. Development of non-peptide ligands of growth factor receptor-bound protein 2-src homology 2 domain using molecular modeling and NMR spectroscopy

    Journal of Medicinal Chemistry, Vol. 54, Núm. 4, pp. 1096-1100

2010

  1. Development of fluorescent ligands for the human 5-HT1A receptor

    ACS Medicinal Chemistry Letters, Vol. 1, Núm. 6, pp. 249-253

  2. Development of molecular probes for the human 5-HT6 receptor

    Journal of Medicinal Chemistry, Vol. 53, Núm. 19, pp. 7095-7106

2008

  1. The medicinal chemistry of agents targeting monoacylglycerol lipase

    Current Topics in Medicinal Chemistry, Vol. 8, Núm. 3, pp. 231-246

2005

  1. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis

    FASEB Journal, Vol. 19, Núm. 10, pp. 1338-1340

  2. Involvement of cannabinoids in cellular proliferation

    Mini-Reviews in Medicinal Chemistry

  3. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT1AR agonists with selectivity over α1- adrenoceptors

    Journal of Medicinal Chemistry, Vol. 48, Núm. 7, pp. 2548-2558

2004

  1. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study

    British Journal of Pharmacology, Vol. 141, Núm. 3, pp. 457-467

  2. Comparison of anandamide transport in FAAH wild-type and knockout neurons: Evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake

    Biochemistry, Vol. 43, Núm. 25, pp. 8184-8190

  3. Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT1A affinity/selectivity

    Bioorganic and Medicinal Chemistry, Vol. 12, Núm. 6, pp. 1551-1557

2003

  1. Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2- a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist

    Bioorganic and Medicinal Chemistry Letters, Vol. 13, Núm. 8, pp. 1429-1432

  2. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    European Journal of Medicinal Chemistry

  3. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase

    Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522

  4. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 18, Núm. 3, pp. 225-231

  5. VR1 receptor modulators as potential drugs for neuropathic pain.

    Mini reviews in medicinal chemistry, Vol. 3, Núm. 7, pp. 729-748

2002

  1. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions.

    Current topics in medicinal chemistry, Vol. 2, Núm. 6, pp. 625-641

  2. Arylpiperazine derivatives acting at 5-HT1A receptors

    Current Medicinal Chemistry, Vol. 9, Núm. 4, pp. 443-469

  3. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT4 receptor antagonists

    Journal of Medicinal Chemistry, Vol. 45, Núm. 22, pp. 4806-4815

  4. Endocannabinoid transporter inhibitors

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Núm. 2, pp. 129-141